In addition to the typical motor symptoms (resting tremor, cogwheel rigidity, bradykinesia, postural instability) of Parkinson's disease (PD), non-motor symptoms are sources of considerable burden in people with PD, especially in elderly patients. The usual non-motor symptoms include cognitive declines, psychiatric disturbances (depression, psychosis, impulse control), autonomic failures (gastrointestinal, cardiovascular, urinary, sexual ability, thermoregulation), sleep difficulties, and pain syndrome. This review article discusses the characteristics, pathophysiology, epidemiology, and management of these symptoms.
Introduction
Parkinson's disease (PD), first described by James Parkinson in 1817, is a chronic, progressive neurodegenerative disorder 1 . The pathologic hallmark is a deterioration of the substantia nigra of yet unknown causes, resulting in a deficiency of dopamine, an important neurotransmitter for the basal ganglia circuit. Its typical clinical symptoms are resting tremor, cogwheel rigidity, bradykinesia, and postural instability. Many affected patients are older than 55 years of age, and men seem to be slightly more predominantly affected than women 2 . While PD is mainly regarded as a movement disorder, patients suffer from not only motor symptoms, but also the non-motor symptoms which are also common and can significantly debilitate patients' activities as well as the quality of life. These complications include cognitive, psychiatric, autonomic, sleep and sensory disorders (Table) . The non-motor symptoms may appear even before the motor symptoms are first noticed. But they are more troublesome in the more advanced stages of PD, when they can become major problems for the patients and often pose a challenge to the treating physicians 3, 4 . With multiple medications often being used to treat PD, their side effects may further exacerbate the problems.
Epidemiology
Because of the varieties of symptoms, the prevalence of non-motor symptoms in PD patients is difficult to delineate precisely. It is estimated that about 16-70% of patients suffer from neuropsychiatric problems, including depression, anxiety, apathy or psychosis [5] [6] [7] . Cognitive deficits affect at least 20-40% of PD patients [8] [9] [10] . Sleep disturbances occur in more than a third of PD patients 11, 12 . Dysautonomia, including constipation, orthostatic hypotension, urinary and sexual dysfunctions, is reported in more than half of the PD patients, according to a questionnaire-based study 13 . This European study and other studies also suggest that autonomic failures, including orthostatic dizziness, bladder dysfunctions, erectile dysfunctions and hyperhidrosis, are more prevalent in PD patients than control individuals without PD. These symptoms had a huge impact on their quality of life [13] [14] [15] . Using a comprehensive symptom survey, Siddiqui et al. 16 reported a significantly higher prevalence rate of increased salivation, dysphagia, decreased bowel movement, and orthostatic dizziness in PD patients compared with controls. Two studies showed that cardiac uptake of metaiodobenzylguanidine, an index of functional integrity and function of postganglionic neurons, was impaired in almost all patients with PD, independent of duration and severity of their parkinsonian symptoms 17, 18 .
Pathophysiology
Since non-motor symptoms comprise a variety of symptoms in different aspects, their involvement must be related to diffuse or multiple brain dysfunctions. Hallucination and psychosis can be related to the dopaminergic system in the prefrontal region. Depression is likely due to the decreased numbers of serotonin 5-hydroxyindolacetic acid (5-HT) neurons in the dorsal raphe nucleus and reduced dopamine neurons in the ventral tegmental area 19, 20 . Cognitive function may be related to the depletion of dopamine in the head of the caudate nucleus, which participates in the basal ganglia-thalamocortical circuits involving different regions of the prefrontal cortex. Lewy body formation is abundant in these regions 21, 22 . Urinary control may be from frontal cortex degeneration or autonomic nervous system dysfunction, and possibly in combination with prostate enlargement. Orthostatic hypotension is likely due to sympathetic denervation of the central control centers located at the dorsal vagal nucleus, nucleus ambiguus, and other medullary centers (caudal raphe nuclei, rostral ventrolateral medulla, and ventromedial medulla). These nuclei mainly control the sympathetic pre-ganglionic neurons via descending pathways 23, 24 . Lewy bodies have been found in the myenteric plexus in PD patients. This explains the reason for constipation because of the loss of dopaminergic cells throughout the gastrointestinal tract 25 .
PD is characterized by a dopaminergic degenerative process affecting neurons in the substantia nigra. This results in the disruption in the basal ganglia circuitry. How the degenerative processes damage both the nigrostriatal system and other brain regions is not completely clear. Braak et al. 26 hypothesized that the degenerative process starts from the base of the brain. The olfactory bulbs may be the first to be involved, followed by the lower brain stem that affects autonomic functions as well as sleep. Subsequently, substantia nigra [26] [27] [28] .
Depression
Depression is a very common feature in patients with PD. The reported prevalence from various studies is between 16% and 70% [5] [6] [7] . Such variations are due to the different diagnostic criteria used in different studies. Major depressive disorder defined by DSM-IV may not be very common in PD patients, but depressive symptoms certainly have a high prevalence rate in PD. It is thought that complex interactions between norepinephrine, serotonin and dopamine systems are interrupted in brains of PD patients. The mechanisms are not clear yet. Some studies revealed decreased concentrations of 5-HT, a serotonin metabolite, in the cerebrospinal fluid and reduced cortical 5-HT1A receptor binding in PD 29 . Another study suggested the role of an allelic variation in the serotonin transporter gene 30 .
The diagnosis of depression in PD can be challenging, since flat affect, psychomotor slowing, fatigue, and decreased libido may be frequently mistaken for PD motor symptoms. The characteristics of depression in PD are decreased energy and motivation, losing interest, feelings of sadness, helplessness and hopelessness, changes in weight, sleep and appetite, irritability, and thoughts of suicide. Approximately 7-32% of PD patients are diagnosed with major depression, according to DSM-IV diagnostic criteria 31 . However, the depression is reported to be qualitatively different in that many depressed PD patients have greater rates of anxiety, pessimism, irrationality, and less guilt and self-reproach, compared with those of non-PD patients with major depression 32, 33 . There can be fluctuations between a normal affect and a depressive state in their emotions. The episodes of depression may be more frequent during the "off" medication stage and may improve when the motor symptoms are better treated 34 . Interestingly, depression has been found to be more prevalent in patients with the akinetic-rigid type of PD, compared with those with the tremor-predominant type, and in patients with right-sided motor symptoms 35, 36 . Furthermore, greater depression is probably associated with greater motor symptom severity in PD 37 .
Reactive depression is another form of depression experienced by newly diagnosed PD patients and others with more advanced disease who are losing independence and control because of changes in motor functioning and feelings of helplessness 6, 25 . Other social factors, including job loss with subsequent changes in income or loss of identity, may also contribute to depression. Concurrent memory difficulty, communication problems, and sleep interruptions, all add to the severity of depression and anxiety. They contribute substantially to increased morbidity and caregiver burdens.
Treating PD patients with depression has not been different from treating patients with other forms of depressive disorders. Selective serotonin reuptake inhibitors (SSRIs) are most frequently used. This is generally safe, although a small number of patients were reported to develop serotonin syndrome from combined use of SSRI and selegiline, a monoamine oxidase B inhibitor 38 . The effectiveness of SSRI in the treatment of PD depression is still not determined. There have not been large-scale, of double-blind, placebo-controlled studies conducted. A meta-analysis found disappointing benefits of SSRI treatment in older PD patients with depression 39 . Other treatments of choice include tricyclic antidepressants. While this class of medications has the additional benefit in reducing tremor by their anticholinergic action, the side effects, including confusion, orthostatic hypotension, dry mouth or constipation, often limit their use. Rarely, electroconvulsive therapy is used in patients with medication-refractory depression.
It may improve motor function in PD patients 40, 41 .
Anxiety
There can be periodic anxiety and panic attacks. Anxiety disorders are more prevalent in PD patients than age-matched controls, although it is often underdiagnosed 42 . The prevalence rate is at least 40% 43 . Panic attacks easily occur in patients who develop erratic motor fluctuations during "off" periods. It usually improves after the patient achieves the "on" state 44 . "On" state dyskinesia may also induce anxiety. Thus, anxiety attacks seem more related with the motor fluctuations in PD patients. Benzodiazepine, buspirone, and SSRI may help reduce such anxiety of PD motor symptoms may be more helpful in reducing anxiety and fearfulness.
Cognitive Decline and Dementia
Dementia in PD may not be evident until the later stages. Although the cognitive decline reported in PD is subtle and does not often interfere with daily functioning, PD patients have been shown to demonstrate cognitive slowing and executive dysfunctioning problems at earlier stages 46 . Longitudinal research has described PD-related cognitive deficits in language, visuospatial functioning, long-term memory, and executive functioning that are greater than those expected from normal aging. The percentage of patients with cognitive deficits is estimated to be approximately 20% 8, 10 . However, the prevalence varies widely according to different studies. For example, a Norwegian study of PD patients indicated that the 8-year prevalence in developing dementia was 78.2% 47 .
The cognitive dysfunction in PD may be a consequence of disruption not only in the primary motor circuit but also in a number of interconnected pathways from the basal ganglia to the cortex. Dopamine depletion in the lateral orbitofrontal and dorsolateral prefrontal circuits has been suggested as a possible mechanism of cognitive impairment in PD 48 . Cholinergic cell loss in the nucleus basalis of Meynert is prominent in PD. The disturbances of dopamine-acetylcholine dependent alterations in synaptic plasticity may also be responsible for dementia in PD 49 .
PD patients at a higher risk of developing demenia include: (1) age older than 70 years; (2) Unified Parkinson's Disease Rating Scale motor score of more than 25 (moderate to advanced impairment); (3) coexisting depression; (4) development of mania, agitation, disorientation or psychosis when treated with levodopa; (5) facial masking at presentation; (6) exposure to psychologic stress; (7) presence of cardiovascular abnormalities; (8) low socioeconomic status and educational level; and (9) predominant bradykinesia, and postural and gait disturbance. Tremor or other parkinsonian signs are less associated with dementia 10, 50, 51 .
Cognitive impairment in PD is usually distinguished from that of Alzheimer's type, which reveals more amnestic quality of memory loss. In contrast, PD patients encompass the clinical symptoms of cognitive slowing, impaired memory recall and retrieval, and executive deficits. These symptoms are summarized as "dysexecutive syndrome", in which acquisition and delayed recall are defective, while recognition memory remains intact 52 . However, the distinctions usually may not be very clear. About 15-30% of demented patients with PD may also have coexisting Alzheimer's disease and exhibit symptoms of impaired language, memory, and visuospatial functioning earlier in the course of the disease, including the presence of aphasia, agnosia, and apraxia 53, 54 . Another important differential diagnosis is dementia with Lewy bodies (DLBs), which also manifests dementia, autonomic failure, and parkinsonian symptoms. As a general rule, DLB patients show fluctuations in mental symptoms, visual hallucinations, and more prominent lower body parkinsonism. The motor symptoms of parkinsonism usually occur together with cognitive decline 55 . Again, the clinical features are frequently not reliable in making a clear differentiation. A confirmed diagnosis usually depends on the results of autopsy. A typical pathologic picture of DLBs shows widespread Lewy bodies located in the neocortex and basal ganglia 56 .
Rivastigmine, an acetylcholinesterase inhibitor that has been used in the symptomatic treatment of patients with mild to moderate Alzheimer's disease, was also shown to be effective in the treatment of dementia in PD 57, 58 . Other cholinesterase inhibitors may also be beneficial, although large-scale randomized controlled studies have yet to be conducted 59 . Memantine, which is an N-methyl-D-aspartate receptor antagonist beneficial in Alzheimer's dementia, has not been shown to be effective in PD dementia 60 . One study even suggested that it worsened both the motor and cognitive functions in PD 61 .
Psychosis and Hallucination
Hallucination occurs in PD, more frequently in the advanced stages. Psychosis and visual hallucination are common, dose-dependent adverse effects of anti-PD medications, in combination with disease progression and medical illnesses 62 . Risk factors include advancing age, presence of dementia, and polypharmacy. Patients who experience hallucination generally have a certain degree of cognitive decline. They also have a worse prognosis, with higher mortality rates 63 . In addition, delusions, paranoid ideation, and delirium may also become more frequent as the disease progresses.
Hallucination is usually visual in nature, in contrast to auditory hallucination in schizophrenia 64 . Patients may report seeing small animals, insects, children, or their deceased relatives or friends. In the early stages, patients retain insight that the hallucinations are not real. Symptoms are commonly more severe toward the evening, known as "sun-downing" 65 . Patients may experience frightening dreams or night terrors that can lead to acting or lashing out during the dream state. Another common delusion is that of spousal infidelity, for either male or female patients 64, 66 . These symptoms can be aggravated by dopaminergic and other psychoactive medications. Any medical illness, even as mild as an upper respiratory tract infection or diarrhea, may trigger or worsen the demented or psychotic symptoms. They are best managed by either simplifying the patient's psychoactive medications or reducing the dopaminergic drugs.
Typical neuroleptics significantly increase extrapyramidal symptoms in PD and should not be used. Atypical neuroleptics, such as quetiapine or clozapine, may be used in the evening to relieve such symptoms [67] [68] [69] . However, not all atypical neuroleptics are safe or free from extrapyramidal side effects. Olanzapine and risperidone were both shown to worsen the motor symptoms in PD and should not be used 70, 71 .
Sleep Disturbance
Sleep disturbances are common problems in PD patients. Because of depression and/or hallucination, patients may become restless at night and have difficulty falling asleep. Those at higher risk for pathologic sleep are male patients with advanced disease, cognitive impairment, drug-induced psychosis, and orthostatic hypotension 72 . After falling asleep, patients may still wake up frequently because of stiffness of their bodies or urinary urgency at night. As a result, they have difficulty achieving restful sleep. Rapid eye movement (REM) behavior sleep disorder (RBD) is very likely to occur. It is characterized by loss of atonia during REM sleep, resulting in excess motor activity during dreaming. It is highly related to neurodegenerative disorders, including PD 73, 74 . Recent studies suggested RBD may occur well before the emergence of PD symptoms. Approximately half of the patients with RBD will eventually develop PD, and so RBD may be an indicator of presymptomatic PD 75 .
Interestingly, the movements during REM sleep show little signs of parkinsonism. This could be attributed to the motor signals from the cortex during REM sleep bypassing the extrapyramidal system 76 . Management of this disorder requires adjusting dopaminergic medications to smaller dosages, especially toward the night. Long-acting dopamine agonists may also be considered 77, 78 . Clonazepam has been widely used in this condition, but side effects such as excessive sedation have to be monitored 72 .
Excessive daytime sleepiness (EDS) is common. In addition to fatigue that many PD patients experience, the lack of sleep during the night also sets up a vicious cycle for poor sleep hygiene. This sleepiness can be disabling, often approaching levels observed in disorders of sudden-onset sleep, namely narcolepsy/ cataplexy. Polysomnographic studies have shown transition from wakefulness to stage II sleep within seconds 79 . In addition, dopaminergic drugs, especially dopamine agonists, can further cause sedation and sudden onset of sleep [80] [81] [82] . Management is usually by adjusting the timing of medications, or breaking the vicious cycle by improving patients' night-time sleep. Modafinil may help relieve EDS. However, while this medicine does not deteriorate PD symptoms, several randomized controlled trials revealed that it either had no significant benefit or produced only modest improvement [83] [84] [85] . A significant portion of patients may suffer restless leg syndrome (RLS) that results in sleep disturbance [86] [87] [88] . It is characterized by an uncomfortable feeling of the lower extremities that urges the patients to move. It occurs mostly when patients are at rest or during the night. Moving or walking will help patients feel better subjectively. It often occurs in combination with the symptoms of periodic limb movement during sleep, a repetitive, myoclonic jerky limb movement present mainly when patients are asleep. Both conditions severely affect the sleep quality of patients. Prevalence of RLS in PD patients was reported to be higher than that in other non-PD patients 3, 89, 90 . The pathophysiology is still unclear, although various central dopaminergic systems are believed to be involved in both PD and RLS 91 . Dopamine agonists, such as ropinirole and pramipexole, are effective in controlling RLS [92] [93] [94] [95] . Levodopa is also effective in controlling the symptoms, although augmentation is a concern. This limits the usefulness of levodopa as a first-line choice for treatment of RLS. Other medications, including gabapentin, clonazepam and opiates, have been shown to relieve RLS symptoms [96] [97] [98] . One study even reported that deep brain stimulation of the subthalamic nucleus also improved RLS 99 .
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Autonomic Dysfunctions
Autonomic dysfunctions in PD patients are manifested in several different systemic symptoms. These generally include cardiovascular (orthostatic hypotension, cardiac arrhythmia), gastrointestinal (gastric dysmotility, indigestion, constipation, and regurgitation), urinary (frequency, urgency or incontinence), sexual (impotence or hypersexual drive), and thermoregulatory (excessive sweating or intolerance of heat or cold) dysfunctions 4, 25 . The pathophysiology of dysautonomia in PD is thought to be from degeneration and dysfunction of the nuclei that mediate autonomic functions, such as the dorsal vagal nucleus, nucleus ambiguus, and other medullary centers (rostral ventrolateral medulla, ventromedial medulla, caudal raphe nuclei), which exert differential control on the sympathetic preganglionic neurons via descending pathways 100 .
Cardiovascular System
Orthostatic hypotension is a particular concern. The symptoms include position-related dizziness, fatigue or even fainting. Position-related dizziness often leads to falls in PD patients. It may be a subtle sign in the early stage of PD and may not manifest as a major problem until later stages 101 . Dopaminergic medications usually do not significantly help. They may even worsen the symptoms, especially with dopamine agonists 102, 103 . Treatment of orthostatic hypotension is mostly symptomatic. For those patients who also take regular antihypertensive medications, the balance between these and Parkinson medications should be sought. Patients are encouraged to drink appropriate amounts of water and consume more salt. They should be taught to get up slowly from a sitting position and wait for a while before initiating their gait to prevent the sudden decrease of blood pressure on positional changes. Compression stockings may also improve the condition. In more severe cases, antihypotensive medications may be necessary to improve orthostatic hypotension symptoms. The commonly used drugs are fludrocortisone (a saltretaining mineralocorticoid) or midodrine (a selective, peripherally acting alpha-adrenergic agonist). In an epidemiologic study, 9.1% of PD patients required such medications to treat orthostatic hypotension 104 .
Gastrointestinal System
Gastrointestinal symptoms are a common problem in PD. Dysphagia, heartburn, medication-related nausea, and constipation are the predominant symptoms 105 .
Constipation is the most frequently encountered problem. It can be one of the early signs even before the appearance of the motor symptoms of PD 13, 106 . Slower bowel movement and decreased mobility exacerbate the severity of constipation. This can especially be a serious problem for older patients, as they do not exercise enough and may not take adequate amounts of fluid. At least 59% of PD patients suffer from constipation as compared with 21% in age-matched non-PD patients 107 . Byrne et al. 108 reported that constipation in PD is commonly a consequence of anorectal sphincter and pelvic floor dysfunctions 108 . Fewer than three bowel passages in a week will raise the clinicians' concern for constipation. Patients are advised to take plenty of high-fiber food (dietary bulk) and fluid. Reducing anticholinergic medications will also help. Regular exercise can improve bowel motility. Stool softeners, laxatives, and enemas may also be used to relieve persistent symptoms 109, 110 .
Dysphagia may become more problematic as PD progresses and can lead to choking and aspiration pneumonia. Softening of foods may help, whereas others may need to thicken their liquids. Evaluation by a speech pathologist or otolaryngologist can be helpful. Patients are instructed not to rush, and to eat and chew thoroughly before swallowing 111 . However, for some patients with advanced disease, a feeding gastrostomy may be necessary to improve nutrition and quality of life and avoid aspiration 112 .
Nausea troubles many PD patients, especially when they suffer the side effects of levodopa, dopamine agonists or other parkinsonian medications. This can be explained by the stimulation of dopaminergic receptors in the brain stem nausea center and the peripheral tissues, including receptors on the gastrointestinal tract, resulting in irregular peristalsis. To correct this condition, sometimes simply changing the medication schedule may help. Other options include extra carbidopa to block the conversion of levodopa to dopamine in the peripheral tissues more effectively. Certain antiemetic (or appetite-increasing) medications, like chlorpromazine, cisapride or metoclopramide, block dopaminergic receptors both peripherally and centrally and should be avoided as they will cause worsening of PD symptoms 113 . . Appropriate dosage of anticholinergics or alpha-blockers helps relieve the frequency problems. The use of dopaminergic medications to improve bladder function has been reported but is generally not reliable 117, 118 .
Sexual dysfunctions, including erectile difficulty, loss of libido, and anorgasmia, are common in male PD patients 119 . Erectile dysfunction was nearly twice as frequent in PD patients, compared with controls from a questionnaire-based study 115 . Patients rarely give information despite its significance on quality of life. Sildenafil has been reported to be effective for erectile dysfunction in patients without obvious cardiovascular risk factors [120] [121] [122] . Other patients may suffer a completely opposite problem, which is sexual impulse control. Patients, particularly those taking dopaminergic medications, may become obsessive and compulsive in gambling, shopping, spending or even sex. Pergolide mesylate, when added to L-DOPA, was reported to significantly improve all sexual functions in younger male PD patients who were still interested in sexual activities 123 . However, some argued that dopamine agonists may induce impulse control disorders in PD, resulting in hypersexuality in these patients 124, 125 . Dopamine agonists did not actually improve erectile dysfunction in these patients. The effects of impulse control difficulties on PD patients will need further investigation.
Thermoregulation
PD patients may experience cold or heat intolerance. A more common problem is excessive sweating (hyperhidrosis). A study found that complaints of sweating disturbances were not correlated with disease severity but did correlate with other symptoms of autonomic dysfunction. Sweating problems occurred predominantly in "off" periods and in "on" periods with dyskinesias. It was almost three times more common than in controls who did not have PD 126 . Excessive sweating occurred mainly on the face, head, and trunk. It may be explained by decreased activation of sweat glands in the palms of the hands, suggesting that axial hyperhidrosis can be a compensatory phenomenon for reduced sympathetic function in the extremities 127 .
This phenomenon results in reduced quality of life of the patients, in the areas of daily activities as well as social interactions 126 . Botulinum toxin injections may relieve local areas of hyperhidrosis, though it has no effect on the body function or thermoregulation.
Conclusion
Non-motor symptoms in PD are usually more complicated and difficult to manage than typical PD motor symptoms. However, they are usually overlooked and not properly treated. Physicians should be aware of the need to evaluate the neuropsychiatric, cognitive, autonomic, and sleep complications of PD. Early recognition of non-motor symptoms is essential, as effective treatment can reduce morbidity and improve the quality of life of PD patients.
